Investing in the GlaxoSmithKline stock offers most retired investors a favorable level of supplemental income. This insight is from Keith Speights, an investor who owns stock market shares of Enterprise Products Partners and Devon Energy.
We want to share this Wall Street-related report with our readers. We believe our followers, who are US stock market investors, can get important ideas that can aid them tremendously in their stock market investing journey.
Based on the article posted online by multinational financial services corporation Nasdaq, Speights initially recommended investing US$100,000 into Enterprise Products Partners and Devon Energy.
Then, he remarked that investing the remaining amount in the GlaxoSmithKline stock will give almost US$1,900 to investors, and they can get their total yearly income from these three stocks close to US$7,700.
Wall Street is especially bullish about the GlaxoSmithKline stock. The consensus 12-month price aim for this stock reflects an upside possibility of approximately 20 percent.
Furthermore, US stock market analysts’ optimism centers largely on GlaxoSmithKline’s medicines for the human immunodeficiency virus or HIV, which carry on delivering robust sales growth. GlaxoSmithKline also has rising stars, including cancer medicine Zejula, respiratory therapies Trelegy Ellipta and Nucala, and lupus drug Benlysta.
GlaxoSmithKline plc, or GSK for short, is a British multinational pharmaceutical firm. The merger of SmithKline Beecham and Glaxo Wellcome led to this London, England-headquartered company’s establishment in 2000.
As among the world’s largest pharmaceutical business establishments after Pfizer, Novartis, Roche, Sanofi, and Merck and Company, GlaxoSmithKline has a primary listing on the London Stock Exchange.
This drugmaker is also a constituent of the FTSE 100 Index. United States-based investors can use their hard-earned investment funds in buying GlaxoSmithKline stocks, with this company having a secondary listing on the New York Stock Exchange.
As of October 2021, the pharmaceutical company has a market capitalization of US$100.06 billion, per the information available on Companiesmarketcap.com. GlaxoSmithKline intends to sell its consumer healthcare department next year to a private equity firm or make it undergo a spinoff.
With this agenda, US stock market analysts see the GlaxoSmithKline stock potentially decreasing its dividend by roughly 31 percent. Retired investors might see their yearly dividends from their investments in Enterprise Products Partners, Devon Energy, and the GlaxoSmithKline stocks near US$7,000.
However, most retired investors would still be satisfied with that supplemental income level, per Speights. We understand that various investors have diverse objectives.
We recommend retired investors invest some of their funds by purchasing some GlaxoSmithKline stocks. It is a dividend stock considerably helpful in retirement as it can provide investors more steady financial returns annually, per the Nasdaq analysis, and can fulfill their target of attaining higher dividend income.